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Abstract
Introduction Although transforming growth factor 1 (TGF1)
is known to be a potent inhibitor of proliferation in most cell
types, it accelerates proliferation in certain mesenchymal cells,
such as articular chondrocytes and nucleus pulposus cells. The
low ability for self-renewal of nucleus pulposus cells is one
obstacle in developing new therapeutic options for
intervertebral disc diseases, and utilizing cytokines is one of the
strategies to regulate nucleus pulposus cell proliferation.
However, the precise cell cycle progression and molecular
mechanisms by which TGF1 stimulates cell growth remain
unclear. The aim of this study was to elucidate a mechanism that
enables cell proliferation with TGF1 stimulation.
Methods We tested cultured rat nucleus pulposus cells for
proliferation and cell cycle distribution under exogenous TGF1
stimulation with and without putative pharmaceutical inhibitors.
To understand the molecular mechanism, we evaluated the
expression levels of key regulatory G1 phase proteins, c-Myc
and the cyclin-dependent kinase inhibitors.
Results We found that TGF1 promoted proliferation and cell
cycle progression while reducing expression of the cyclin-
dependent kinase inhibitors p21 and p27, which are
downregulators of the cell cycle. Robust c-Myc expression for 2
h and immediate phosphorylation of extra cellular signal
regulated kinase (ERK1/2) were detected in cultures when
TGF1 was added. However, pretreatment with 10058-F4 (an
inhibitor of c-Myc transcriptional activity) or PD98059 (an
inhibitor of ERK1/2) suppressed c-Myc expression and ERK1/2
phosphorylation, and inhibited cell cycle promotion by TGF1.
Conclusions Our experimental results indicate that TGF1
promotes cell proliferation and cell cycle progression in rat
nucleus pulposus cells and that c-Myc and phosphorylated
ERK1/2 play important roles in this mechanism. While the
difference between rat and human disc tissues requires future
studies using different species, investigation of distinct
response in the rat model provides fundamental information to
elucidate a specific regulatory pathway of TGF1.
Introduction
Transforming growth factor 1 (TGF1 )  i s  k n o w n  t o  b e  a
potent inhibitor of proliferation in most cell types, including
keratinocytes [1], endothelial cells [2-4] lymphoid cells [5-7]
and mesangial cells [8]. Conversely, TGF1 stimulates prolif-
eration in certain mesenchymal cells such as bone marrow
derived mesenchymal stem cells (BM-MSCs) [9], chondro-
cytes [10-12] and cells with osteoblastic phenotypes [13].
However, the exact mechanism of stimulation of cell prolifera-
tion by TGF1 has not been elucidated.
Previous studies suggested that endogenous c-Myc mRNA
and protein decrease rapidly when TGF1 inhibits cell growth
[14-17]. c-Myc is a helix-loop-helix-leucine zipper oncoprotein
AC: articular chondrocytes; BM-MSCs: bone marrow derived mesenchymal stem cells; BSA: bovine serum albumin; CDK: cyclin dependent kinase; 
CKIs: cyclin dependent kinase inhibitors; DMEM: Dulbecco's modified Eagle medium; DPBS: Dulbecco's phosphate-buffered saline; ERK1/2: extra-
cellular signal regulated kinase 1/2; FACS: fluorescence-activated cell sorting; FBS: fetal bovine serum; GSK-3: glycogen synthase kinase-3; KT: 
keratinocytes; MAPK: mitogen activated protein kinase; Max: Myc-associated factor X; MEK: MAP/ERK kinase; MEM: minimum essential medium; 
MKK: MAP kinase kinase; NP: nucleus pulposus; PVDF: polyvinylidene difluoride; RT-PCR: reverse transcriptase-polymerase chain reaction; TBST: 
Tris-buffered saline/Tween; TGF1: transforming growth factor 1; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; SEM: 
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that plays an important role in cell cycle regulation [18]. It has
been also shown that elevated c-Myc activity is able to abro-
gate the cell cycle suppressing effect of TGF1; the mouse
keratinocyte cell line (BALB/MK) constitutively expresses
endogenous c-myc, and showed resistance to the arrest of
growth by TGF1 [19]. Similarly, c-myc-transfected Fisher rat
3T3 fibroblasts showed upregulation in colony formation in
soft agar with TGF1 treatment [20]. At the same time, these
investigators suggested that TGF is a bifunctional regulator
of cellular growth [19,20].
Considering these findings, we hypothesized that the cells
that show mitogenic response to TGF1 have a unique mech-
anism dependent on endogenous c-Myc. We determined the
mitogenic effect of TGF1 on cultured rat nucleus pulposus
cells and whether the small-molecule c-Myc inhibitor, 10058-
F4, obstructed cell proliferation caused by exogenous TGF1.
This inhibitor is a recently identified compound that inhibits the
association between c-Myc and Myc-associated factor X
(Max). Because c-Myc/Max heterodimers are necessary for
binding E-box DNA in the target gene, the interruption of their
association inhibits the transcriptional function of c-Myc [21].
Secondly, to suppress expression of c-Myc in protein level, we
tested an inhibitor of extracellular signal regulated kinase
(ERK)1/2, PD98059 [22]. This was investigated since, it has
been reported that mitogen activated protein kinase (MAPK)
subtype ERK1/2 mediates TGF1 signaling in rat articular
chondrocytes [23] and stabilizes c-Myc protein expression
[24].
To understand the molecular mechanism of cell cycle regula-
tion by TGF1, we utilized western blot analysis. The cell cycle
is known to be controlled by positive and negative regulators.
The positive regulators are cyclin and cyclin-dependent kinase
(CDK) complexes [25]. Cell cycle progression through G1 into
S phase requires cyclin D-CDK4/6 and cyclin E-CDK2, which
phosphorylate the retinoblastoma protein [26]. CDK inhibitors
(CKIs) are the negative regulators and are grouped into two
families [27]. The INK4 family (p15, p16, p18, p19 and p20)
only bind and inactivate cyclin D-CDK4/6 complex, while the
Cip/Kip family (p21, p27, and p57) show broader substrate
specificity inactivating both cyclin D-CDK4/6 and cyclin E-
CDK2 kinase complexes [28]. We examined the expression of
p15INK4, p21WAF1/Cip1 and p27Kip1, which are known to prevent
cell cycle progression under the growth inhibitory effect of
TGF1 [29-32].
The aim of the present study was therefore to reveal the role
of c-Myc in mitogenic response to TGF1 in nucleus pulposus
cells. The study was designed to (1) analyze the effect of
TGF1 on cell proliferation and the cell cycle progression in
nucleus pulposus cells, (2) determine if c-Myc transcription
inhibitor obstructed the effect of TGF1, and (3) determine the
role of ERK1/2 in stabilizing the expression of c-Myc.
Materials and methods
Antibodies and reagents
Recombinant human TGF1 was obtained from PeproTech
Pharmacological (London, UK). Pharmacological c-Myc inhib-
itor, 10058-F4, ((Z, E)-5-(4-Ethylbenzylidine)-2-thioxothiazoli-
din-4-one), which inhibits c-Myc transcriptional activity was
supplied by Calbiochem (Darmstadt, Germany). Pharmaco-
logical MAPK/ERK kinase inhibitor PD98059 was from
Upstate (Lake Placid, NY, USA). Polyclonal rabbit antibodies
against rat phospho-MAPK (ERK1/2) (Thr202/Tyr204), p44/
42 MAPkinase (ERK1/2), and p27 Kip1 were from Cell Sign-
aling Technology (Beverly, MA, USA). Polyclonal rabbit anti-
bodies against rat p15 INK4b, p21 WAF1/Cip1 and c-Myc
were from Abcam (Cambridge, UK) and monoclonal mouse
antibody for beta-Actin was from Sigma-Adrich Corp. (St
Louis, MO, USA).
Cell culture
All animal experiments were performed with approval from the
Tokai University animal study institutional review board
(No.073008). A total of 14 female Sprague-Dawley rats (12
months old; CLEA Japan Inc., Tokyo, Japan) were utilized for
the entire study and the cells from at least 3 animals were
applied to each experiment. Cryopreserved primary passage
rat epidermal keratinocytes were obtained from Cell Applica-
tions Inc. (San Diego, CA, USA) and maintained in growth
medium (Cell Applications Inc.). Cells from rat intervertebral
disc tissues were isolated and processed as previously
described [33]. Briefly, the nucleus pulposus was harvested
from coccygeal discs of rats and suspended in Dulbecco's
phosphate-buffered saline (DPBS; DS Pharma Biomedical,
Osaka, Japan) with 0.05% trypsin/0.53 mM Ethylenediamine-
tetraacetic acid (EDTA; Gibco Invitrogen Corp., Carlsbad, CA,
USA) added to achieve final concentrations of 0.01% trypsin
and 0.1 mM EDTA and allowed to digest at 37°C for 15 min.
Chondrocytes from articular cartilage were prepared following
the method of Tukazaki et al. [10]. Cartilage slices from knee
joints of rats were digested with 0.05% trypsin and 0.53 mM
EDTA (Gibco Invitrogen) at 37°C for 30 min, followed by 0.3
mg/mL collagenase P (Roche Diagnostics GmbH, Mannheim,
Germany) at 37°C for 4 h. The isolated nucleus pulposus cells
and articular chondrocytes were cultured in Dulbecco's modi-
fied Eagle medium: Nutrient Mixture F-12, 1:1 Mixture (DMEM/
F-12) (Wako Pure Chemical Industries Ltd., Osaka, Japan),
containing 10% fetal bovine serum (FBS; Gibco Invitrogen),
100 U/mL penicillin (Gibco Invitrogen) and 100 g/mL strep-
tomycin (Gibco Invitrogen), at 37°C in 5% CO2 humidified
atmosphere. The medium was replaced twice a week and the
cells were trypsinized and subcultured before the cultured
cells reached confluency. The nucleus pulposus has been
reported to consist of at least two major cell populations, noto-
chordal cells and chondrocyte-like cells [34,35]. Because
cells obtained from the rat disc tissues were variable in mor-
phology until the second passage, we expanded the culture to
the third or fourth passage to prepare enough number of theAvailable online http://arthritis-research.com/content/10/6/R140
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morphologically uniformed cells from each animal. Conversely,
because articular chondrocytes were morphologically uniform
since primary culture, the second passage was used for the
experiments. With regard to keratinocytes, they will not prolif-
erate if keratinization is triggered by passage. Therefore, the
primary culture was applied for the experiment in the medium
specified by the supplier. Nucleus pulposus and articular
chondrocytes were subjected to the experiments using Opti
Minimum Essential Medium (Opti-MEM, Gibco Invitrogen).
Serum deprivation was performed with 24 h incubation with
medium containing 2% FBS followed by 2 h incubation with
medium containing 0.5% FBS; 0.5% FBS was fed to maintain
cell adhesion throughout every experimental period. All exper-
iments were performed at least three times to confirm consist-
ency.
Reverse transcriptase-polymerase chain reaction (RT-
PCR)
Cells cultured in serum-deprived medium were treated with
and without 5 ng/mL TGF1 for 24 h. The cells were then har-
vested and total RNA was isolated using the SV Total RNA
Isolation System (Promega, Madison, WI, USA), which
included DNase digestion and spin column purification. Prim-
ers for rat c-myc, p15, p21, p27 and -actin were designed
based on the coding sequences from GenBank ([Gen-
bank:BC091699, AF474979, BC100620, NM_031762,
NM_031144] respectively), and synthesized by Invitrogen. For
c-myc  the primers used were CAACGTCTTGGAACGT-
CAGA (forward) and CTCGCCGTTTCCTCAGTAAG
(reverse). For p15 the primers used were CAGAGCTGTT-
GCTCCTCCAC (forward) and CGTGCAGATACCTCG-
CAATA (reverse). For p21  the primers used were
AGCAAAGTATGCCGTCGTCT (forward) and ACACGCTC-
CCAGACGTAGTT (reverse). For p27 the primers used were
ATAATCGCCACAGGGAGTTG (forward) and CCA-
GAGTTTTGCCCAGTGTT (reverse). For -actin, the primers
were AGCCATGTACGTAGCCATCC (forward) and CTCT-
CAGCTGTGGTGGTGAA (reverse). For each sample, 2 g of
total RNA was reverse transcribed into cDNA using Multi-
Scribe Reverse Transcriptase (Applied Biosystems, Foster
City, CA, USA) and oligo(dT) primers (Applied Biosystems).
For PCR 5 L of cDNA template was amplified in a 25-L
reaction volume of GeneAmp PCR buffer (Applied Biosys-
tems), containing 5.5 mM MgCl2, 200 M of each dNTP, 0.5
M of appropriate primer pairs and 1 unit of AmpliTaq Gold
DNA polymerase (Applied Biosystems). The reaction mixture
was kept at 95°C for 10 min for a 'hot-start', followed by PCR
of 31 cycles for p15, 28 cycles for p21, 27 cycles for p27, 30
cycles for c-myc  and 26 cycles for -actin. Each cycle
included denaturation at 95°C for 15 s, followed by annealing
and extension at 61°C for 1 min. A total of 10 L of each PCR
product was applied to 3% agarose gel for electrophoresis.
Resolved bands on the gels were visualized with ethidium bro-
mide on a densitograph system (ATTO Biotechnologies Inc.,
Tokyo, Japan).
Cell proliferation assay
To determine cell proliferation, nucleus pulposus cells were
plated in 96-well plates at a density of 3,000 cells/well. The
cells were allowed to adhere for 24 h in OptiMEM containing
2% FBS. The medium was replaced with OptiMEM containing
0.5% FBS and recombinant human TGF1 in final concentra-
tions of 0 (control), 5, or 20 ng/mL. For experiments using
pathway specific inhibitors, appropriate concentrations of
10058-F4 or PD98059 were added to the medium as concen-
trated stock solutions dissolved in dimethyl sulfoxide (DMSO,
Wako). The solvent alone was added at 0.08% to serve as the
vehicle control. During the 6 days of culture, the culture media
were replaced on day 3 with the appropriate medium. After
cultivation for the scheduled period, cell numbers were deter-
mined using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT; Wako) assay [36]. Briefly, the cul-
ture medium was replaced with 0.1 mL of MTT solution (0.5
mg/mL MTT) in serum-free DMEM without phenol red (Gibco
Invitrogen). The cells were incubated at 37°C for 2 h, and then
the MTT solution was replaced by 0.2 mL of solubilizer solution
(80% isopropanol; 20% DMSO; 4% Tween 20) and mixed.
The absorbance at 562 nm was determined using a microplate
reader (SPECTRA MAX 250, Molecular Devices, Sunnyvale,
CA, USA). The cell number was calculated based on the
absorbance according to a standard curve of rat nucleus pul-
posus cells prepared prior to the experiments. The wells for
each experimental condition were replicated five times and the
representative results from three individual experiments were
shown.
Cell cycle analysis by fluorescence-activated cell sorting 
(FACS)
The cells were trypsinized, washed and seeded in 25 cm2
flasks at 1 × 105 cells/flask. The cells were allowed to adhere
for 24 h in medium containing 2% FBS. The culture medium of
each flask was then replaced with medium containing 0.5%
FBS. The appropriate concentrations of 10058-F4 or
PD98059 were then added to this medium as concentrated
stock solutions dissolved in DMSO. After incubation for 2 h,
TGF1 (5 or 20 ng/mL) was added to the cultures. After an
additional incubation period of 24 h, cell cycle distribution of
the nucleus pulposus cells was analyzed by FACS after DNA
staining with propidium iodide using the CycleTEST™ PLUS
(BD PharMingen, San Diego, CA, USA) kit. CELLQuest (BD
PharMingen) and ModiFit LT (BD PharMingen) software was
used for calculations of cell acquisition and analysis. Each
experiment was duplicated and the results from three individ-
ual experiments were shown.
Western blot
The cells were lysed in ice-cold cell lysis buffer (50 mM Tris/
HCl, pH7.5; 2 mM CaCl2; 1% TritonX-100) containing pro-
tease and phosphatase inhibitors (0.5 mM phenylmethylsulfo-
nyl fluoride (PMSF); 1/50 Complate, a protease inhibitor
cocktail (Roche Molecular Biochemicals, Mannheim, Ger-Arthritis Research & Therapy    Vol 10 No 6    Nakai et al.
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many); 1 mM Na3VO4 and 1 mM NaF). Cell lysates were soni-
cated for 10 s to shear the DNA, then centrifuged at 10,000 g
for 10 min at 4°C. The supernatant was collected and its total
protein concentration was determined using the DC Protein
Assay Reagent (Bio-Rad, Hercules, CA, USA). Equal amounts
of protein were diluted with sodium dodecyl sulfate (SDS)
sample buffer, (reducing conditions were used only for p21)
boiled for 5 min, and electrophoresis performed using SDS-
polyacrylamide gel electrophoresis (SDS-PAGE). The protein
bands separated in the gel were electrotransferred by elec-
troblotting to a polyvinylidene difluoride (PVDF) membrane fil-
ter (Bio-Rad). The membrane was then blocked with 3% w/v
bovine serum albumin (BSA, Serologicals, Kankakee, IL, USA)
in Tris-buffered saline/Tween (TBST: 50 mM Tris, pH 7.6; 150
mM NaCl; 0.1% Tween-20) for 1 h at room temperature. Incu-
bation with the indicated primary antibodies overnight at 4°C
in 1% BSA in TBST followed this step. After washing in TBST,
the membrane was incubated with secondary anti-IgG anti-
body conjugated with horseradish peroxidase (Amersham Life
Science, Arlington Heights, IL, USA) for 1 h at room tempera-
ture. The signals were detected using enhanced chemilumi-
nescence reagent (ECL Plus, Amersham Pharmacia Biotech,
Bjorkgatan, Sweden).
Statistical analysis
The data are presented as the mean and standard error of the
mean (SEM). Statistical analysis was performed basically by
non-repeated measures analysis of variance (ANOVA) except
for the cell cycle experiment, where repeated measures
ANOVA was used. When a p-value of < 0.05 was found, the
Student-Newman-Keuls test for multiple pair comparisons
was used. **Indicates highly significant differences (p < 0.01),
* indicates significant differences (p < 0.05) throughout.
Results
Different response to TGF1 treatment in c-Myc mRNA 
expression dependent on cell type
To investigate endogenous c-Myc mRNA expression and the
influence of TGF1 treatment on cells derived from different
organs, we analyzed gene expression in rat keratinocytes,
nucleus pulposus cells, and articular chondrocytes. As shown
in Figure 1a, c-Myc mRNA decreased in rat keratinocytes with
TGF1 treatment, while it was unchanged in nucleus pulposus
cells and articular chondrocytes. Further analyses of nucleus
pulposus cells indicated that levels of p21 mRNA decreased
with TGF1 treatment and that levels of c-Myc mRNA were
downregulated at the 60 and 120 min time points (Figure 1b).
Differences in concentration of FBS in the medium did not
Figure 1
Effect of transforming growth factor 1 (TGF1) treatment on mRNA expression in different cell types (a), Cells were treated with or without 5 ng/mL  TGF1 for 24 h Effect of transforming growth factor 1 (TGF1) treatment on mRNA expression in different cell types (a), Cells were treated with or with-
out 5 ng/mL TGF1 for 24 h. The expression of c-myc in nucleus pulposus cells (NP), in articular chondrocytes (AC) and keratinocytes (KT) are 
presented. The expression of p15, p21 and p27 in NP was also determined. Time course of c-myc expression in NP treated with 5 ng/mL TGF1 
(b). The graph shows the relative intensities of c-myc bands normalized for -actin levels by densitographic analysis. Incubation for 24 h with medium 
containing various concentrations of fetal bovine serum (FBS) did not alter the level of c-myc expression in NP (c). The reverse transcription-polymer-
ase chain reaction (RT-PCR) was performed on total RNA extracted from the cells. -actin was used as an internal control.Available online http://arthritis-research.com/content/10/6/R140
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alter the expression of c-Myc mRNA in nucleus pulposus cells
(Figure 1c).
TGF1 treatment enhanced the proliferation of nucleus 
pulposus cells
To determine the effect of TGF1 on cell proliferation, cell
number was measured at the given time intervals. Treatment
was with either 5 or 20 ng/mL TGF1 upregulated cell prolif-
eration on days 3 and 6 (up to 160% compared to the day 3
control (Figure 2)). The statistical significance among the
groups in this proliferation assay by ANOVA was p = 4.408E-
7. The significances of individual differences by the multiple
pair comparisons are shown in Figure 2 (**p < 0.01, *p <
0.05).
Influence of pathway inhibitors blocked cell growth 
under TGF1 stimulation
As nucleus pulposus cells maintained c-Myc mRNA expres-
sion under TGF1 stimulation (Figure 1a,b), we hypothesized
that c-Myc plays a central role in TGF1 signaling for cell
growth stimulation. Additionally, to examine the possibility of
involvement of the MAPK pathway in regulation of c-Myc sta-
bility, we devised serial experiments using the pathway spe-
cific inhibitors 10058-F4, an inhibitor of c-Myc transcriptional
activity, and PD98059, an inhibitor of extracellular signal reg-
ulated kinase (ERK1/2). As shown in Figure 3, 5 or 20 ng/mL
TGF1 treatment increased the nucleus pulposus cell number
(up to 160%, p < 0.01) compared with control. Pretreatment
with the c-Myc inhibitor, 10058-F4, caused a dose-dependent
significant decrease in cell number (from 32% to 79%, com-
pared with the TGF1-treated group, p < 0.01). The 20-ng/mL
TGF1-treated cultures showed higher resistance to the inhib-
itory effect of 10058-F4 (8 and 12 M) than 5 ng/mL TGF1.
The statistical significance of this experiment using 10058-F4
was p = 1.116E-18.
Similar results from the cell proliferation assay using the
ERK1/2 inhibitor (Figure 4), demonstrated that while treatment
with 5 or 20 ng/mL TGF1 increased the nucleus pulposus
cell number (up to 130% compared with control, p < 0.05),
pretreatment with the ERK1/2 inhibitor, PD98059, caused a
significant decrease in cell number (from 66% to 76% com-
pared with TGF1-treated group, p < 0.01). In contrast to the
10058-F4 results, the differences were not clearly dose-
dependent. The statistical significance of this experiment
using PD98059 was p = 1.334E-8.
Effects of TGF1 and pathway inhibitors on cell cycle 
distribution in nucleus pulposus cells
We then used flow cytometry to determine cell cycle progres-
sion by quantifying DNA. Effects of inhibition of c-Myc tran-
scriptional activity and inhibition of ERK1/2 activity in the
presence of 5 ng/mL TGF1 were determined. After serum
deprivation, 79.0% of nucleus pulposus cells were in the G0/
G1 phase, 10.9% in the S phase, and 10.1% in the G2/M
phase (Figure 5a). Treatment with TGF1 for 24 h (Figure 5b)
significantly increased the percentage of cells in the S phase
to 26.4%, indicating that TGF1 did not cause cell cycle
Figure 2
Nucleus pulposus cell proliferation is upregulated by TGF1 treatment Nucleus pulposus cell proliferation is upregulated by TGF1 treat-
ment. Cells were plated in 96-well plates in medium containing 2% 
fetal bovine serum (FBS) for 24 h. This medium was replaced with 
medium containing 0.5% FBS and cells were treated with 5 or 20 ng/
mL transforming growth factor 1 (TGF1). Cell proliferation was evalu-
ated by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) assay on days 3 and 6 after treatment. Five replicates 
per experimental condition were made. Data are normalized to values 
obtained for cells cultured for 3 days in 0.5% FBS containing medium 
and shown as mean ± standard error of the mean (SEM) (*p < 0.05, 
**p < 0.01).
Figure 3
c-Myc transcription inhibition prevents transforming growth factor 1  (TGF1)-stimulated cell proliferation c-Myc transcription inhibition prevents transforming growth factor 
1 (TGF1)-stimulated cell proliferation. Serum-deprived cells in 96-
well plates were treated with 5 or 20 ng/mL TGF1 (abbreviated to T) 
with or without 8, 12, 16 M 10058-F4. Cell proliferation was evalu-
ated by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) assay on day 3 after treatment. Five replicates per 
experimental condition were made. Data are normalized to values 
obtained for untreated cells cultured in 0.5% serum containing medium 
and represented as mean ± standard error of the mean (SEM) (**p < 
0.01 when compared with control, #p < 0.01 when compared with the 
TGF1-treated group).Arthritis Research & Therapy    Vol 10 No 6    Nakai et al.
Page 6 of 12
(page number not for citation purposes)
arrest but acted as a mitogen, unlike its action in some other
cell types. In contrast, marked decrease in the percentage of
cells in the S phase were observed in the presence of 10058-
F4, 4.5% (Figure 5c) or PD98059, 8.4% (Figure 5d). In addi-
tion, increase in the G0/G1 phase were found when cells were
treated with these inhibitors (87.7% (Figure 5c) and 85.6%
(Figure 5d), respectively), compared to control (79.0% (Figure
5a)). This indicates that these inhibitors have caused cell cycle
arrest in the G0/G1 phase even with treatment with TGF1.
The results obtained from three different rats are shown in Fig-
ure 6. Although the percentages of cells in the S phase differ
among individuals, these inhibitors both seem to block the
mitogenic effect of TGF1 completely. The statistical signifi-
cance by the repeated measures ANOVA of the cell cycle
experiment was p = 3.213E-3.
TGF1 did not abolish c-Myc expression but decreased 
CDKIs p21 and p27
In parallel experiments, we evaluated the expression levels of
key regulatory G1 phase proteins c-Myc, p15, p21 and p27
utilizing western blotting. As seen in Figure 7, TGF1 treat-
ment (b) did not abolish c-Myc expression, but pretreatment
with either 10058-F4 (c) or PD98059 (d) diminished the level
of expression. In contrast, TGF1 treatment showed the low-
est levels of p21 and p27 when compared with other experi-
mental conditions. Note that pretreatment with either 10058-
F4 or PD98059 upregulated the levels of p21 and p27 com-
pared to TGF1 treatment. However, no distinguishable
change was observed in p15 expression.
Mitogenic effect of TGF1 is supported by coexpression 
of c-Myc and phospho-ERK1/2
To understand the molecular mechanism underlying TGF1-
mediated cell cycle modulation, we performed a time-course
Figure 4
The inhibition of extracellular signal regulated kinase (ERK)1/2 phos- phorylation prevents transforming growth factor 1 (TGF1)-stimulated  cell proliferation The inhibition of extracellular signal regulated kinase (ERK)1/2 
phosphorylation prevents transforming growth factor 1 (TGF1)-
stimulated cell proliferation. Serum-deprived cells in 96-well plates 
were treated with 5 or 20 ng/mL TGF1 (abbreviated to T) with or with-
out 10, 20, 30 M PD98059. Cell proliferation was evaluated by the 3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
assay on day 3 after treatment. Five replicates per experimental condi-
tion were made. Data are normalized to values obtained for untreated 
cells cultured in 0.5% serum containing medium and represented as 
mean ± standard error of the mean (SEM) (*p < 0.05, **p < 0.01 when 
compared with control, #p < 0.01 when as compared with TGF1-
treated group).
Figure 5
Cell cycle distribution of nucleus pulposus cells Cell cycle distribution of nucleus pulposus cells. Serum-deprived nucleus pulposus cells were cultured with no supplements for 24 h (a). The 
cells were treated with 5 ng/mL transforming growth factor 1 (TGF1) for 24 h (b). At 2 h before the addition of TGF1, the cells were treated with 
16 M 10058-F4 (c), or with 30 M PD98059 (d). The cells were harvested 24 h after the addition of TGF1 and the nuclei were stained with pro-
pidium iodide. DNA histograms were generated using flow cytometry. Each plot represents the analysis of 10,000 events. The histograms present 
typical results and the percentage of cells in G0/G1, S and G2/M phases are shown as the average of duplicated measurements.Available online http://arthritis-research.com/content/10/6/R140
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study on c-Myc and phospho-ERK1/2. Serum-deprived cells
were pretreated with or without 10058-F4 or PD98059 then
treated with TGF1 for different time periods. The cells were
harvested and whole cell lysates were analyzed for the expres-
sion of c-Myc, phospho-ERK1/2, and total ERK1/2 by western
blot. Robust c-Myc expression from the beginning was sup-
pressed at 6 h and ERK1/2 was immediately phosphorylated
(activated) by 0.5 to 2 h in TGF1-treated preparations (Figure
8a). Both c-Myc and phospho-ERK1/2 were detected
throughout the experimental period. The lane on the far right
indicates the result of 24 h treatment with 10% FBS in which
c-Myc and phospho-ERK1/2 appear distinctly (Figure 8a).
These data indicate that coexpression of c-Myc and phospho-
ERK1/2 correlates with vigorous cell proliferation.
By contrast, pretreatment with the ERK inhibitor PD98059
diminished the expression of c-Myc and mainly blocked the
phosphorylation of ERK1 induced by TGF1 treatment (Figure
8b). A single isoform corresponding to phospho-ERK2 was
detected at all time points; this suggests that c-Myc expres-
sion under TGF1 stimulation requires activated ERK1/2,
especially ERK1. Similarly, pretreatment with the c-Myc inhib-
itor 10058-F4 unexpectedly decreased c-Myc expression and
interrupted the phosphorylation of ERK1/2 induced by TGF1
(Figure 8c). The expression of phospho-ERK1/2 was delayed
until the 2-h time point and disappeared after 12 h in spite of
coexistent TGF1. These data indicate that the inhibition of c-
Myc transcriptional activity diminished the level of c-Myc pro-
tein itself and also downregulated the phosphorylation (activa-
tion) of ERK1/2.
The results of these blot analyses reveal that the effect of the
TGF1 signal can be mitogenic when c-Myc and phospho-
ERK1/2 are both expressed in nucleus pulposus cells.
Discussion
Although TGF1 is a potent inhibitor of growth in most cell
types, it has been shown to stimulate growth of certain mes-
enchymal cells in culture, such as mouse BM-MSCs [9], rat
and avian articular chondrocytes [10,11,23,37], human nasal
septal chondrocytes [12], and cells with an osteoblastic phe-
notype from rat parietal bone [38] and from calvariae of 1-day-
old mice [13]. In these previous investigations, growth stimu-
lation was shown by upregulation in proliferation or in [3H]-thy-
midine uptake. With regard to intervertebral disc cells, the
enhancement of colony formation of human annulus fibrosus
cells and increase in density of nucleus pulposus cells in three-
dimensional scaffold cultures have been reported [39,40].
In the present study, we found that TGF1 significantly stimu-
lated growth of nucleus pulposus cells (Figure 2). To ascertain
the effects of TGF1, we examined the cell cycle regulatory
effect of TGF1 in rat nucleus pulposus cells in vitro.
TGF1 regulates gene expression through Smad transcription
factors [41-43]. When TGF1 inhibits cell growth, a rapid
decrease in endogenous c-Myc mRNA and protein has been
observed [14-17]. c-Myc is a transcription factor that pro-
motes cell growth and proliferation, and under certain condi-
tions, apoptosis, and tumor cell immortalization [44]. Levels of
c-Myc are increased or decreased in response to mitogenic or
growth inhibitory stimuli, respectively [17]. It is notable that c-
myc transfected Fisher rat 3T3 fibroblast have a proliferative
Figure 6
Effects of inhibitors and transforming growth factor 1 (TGF1) on cell cycle progression Effects of inhibitors and transforming growth factor 1 (TGF1) on cell cycle progression. Serum-deprived nucleus pulposus cells were 
treated with or without inhibitors (16 M 10058-F4, or 30 M PD98059) then treated with 5 or 20 ng/mL TGF1 for 24 h. The percentage of cells 
in S-phase was determined with fluorescence-activated cell sorting (FACS). Black bar, white bar and gray bar indicate the results obtained for three 
rats respectively. (*p < 0.05)Arthritis Research & Therapy    Vol 10 No 6    Nakai et al.
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response to TGF1 [20], and that the mouse keratinocyte cell
line (BALB/MK) expressing the chimeric estrogen-inducible
form of c-myc-encoded protein (mycER) suppresses the
growth-inhibitory effect of TGF1 [19].
As shown in Figure 1, TGF1 treatment decreased c-Myc
mRNA after 24 h in keratinocytes, while nucleus pulposus
cells and articular chondrocytes showed a constant level of c-
Myc mRNA. In keratinocytes, we confirmed earlier findings
[14,15]. In contrast, nucleus pulposus cells and articular
chondrocytes respond differently to TGF1 treatment.
Although the passage numbers of these cultures are different,
we used all of the cultures at the constantly proliferative stage.
Considering that keratinocytes has been reported to be
growth arrested by TGF1 [1], these results suggest that c-
Myc mRNA expression correlates with the mitogenic response
of the cells to TGF1 stimulation. To investigate the effects of
c-Myc on cell growth under TGF1 stimulation, we inhibited c-
Myc function in nucleus pulposus cells using specific inhibi-
tors.
The mitogenic response to TGF1 suppressed by 
pathway inhibitors
Figure 7a,b indicate that the same levels of endogenous c-Myc
protein were detected in nucleus pulposus cells, independent
of TGF1 treatment. The cell cycle distribution in TGF1-
treated cells (Figure 5b) indicates a large increase in cells in
the S phase, associated with the suppression of p21 and p27
which belong to the Cip/Kip family of cyclin-dependent kinase
inhibitors (CKIs) (Figure 7a,b). By contrast, pretreatment with
either 10058-F4, a c-Myc, inhibitor or PD98059, an ERK1/2
inhibitor, arrested cell proliferation and cell cycle progression
when coexistent with TGF1 (Figures 3, 4, 5, 6). Additionally,
both inhibitors suppressed c-Myc expression while upregulat-
ing p21 and p27 expression (Figure 7c,d) compared to
TGF1-treated cells (Figure 7b). The elevation of p15, p21
and p27 has been reported to be the main cause of cell cycle
arrest by TGF1 [29-32]. We therefore analyzed the expres-
sion of these three CKIs, but found that p21 and p27 were
decreased by TGF1, while there was no change in p15
expression (Figure 7). The findings that TGF1 did not cause
cell cycle arrest in nucleus pulposus cells and that it
decreased p21 and p27 expression can be attributed to the
sustained c-Myc expression. Previous investigations have sug-
gested the special regulation of CKIs under TGF1, mediated
by an elevated level of c-Myc [45-47].
The immediate phosphorylation of ERK1/2 with robust c-
Myc expression for 2 h after TGF1 treatment
In the time course study, the top panel shows TGF1 treat-
ment kept the robust c-Myc expression for 2 h but downregu-
lated it after 6 h (Figure 8a). The downregulation of c-Myc was
considered to result from the downregulation of c-Myc mRNA
transcription by TGF1 through the Smad pathway [16]. As
shown in Figure 1b, the level of c-Myc mRNA was downregu-
lated at 60 min and recovered after 240 min. In the protein lev-
els, distinct recovery of c-Myc expression was not detected;
nonetheless it was sustained for 24 h. The second panel in
Figure 8a shows that TGF1 induces the immediate phospho-
rylation (activation) of ERK1/2; this observation agrees with an
earlier study using rat articular chondrocytes by Hirota et al.
[48]. ERK1 and ERK2 are subtypes of MAPKs activated by a
diverse array of extracellular stimuli [49]. The phosphorylation
of ERK1/2 in nucleus pulposus cells has been reported to be
critical for survival in a hypoxic environment [50]. We also
detected marked phosphorylation of ERK1/2 and c-Myc
expression in 10% FBS-added cultures. Therefore, growth
factors can be considered to drive c-Myc expression and
phosphorylation of ERK1/2 in nucleus pulposus cells. How-
ever, serum-deprived cells with no supplements (time 0 in Fig-
ure 8a) expressed c-Myc, but no phosphorylated ERK1/2.
These results suggest that c-Myc itself does not enhance cell
growth, but acts as a mediator of exogenous growth stimuli.
Figure 7
Western blot analysis of cell cycle regulators Western blot analysis of cell cycle regulators. After 24 h incubation 
in a medium containing 2% fetal bovine serum (FBS), this medium was 
replaced with medium containing 0.5% FBS. Nucleus pulposus cells 
were cultured with no supplements for an additional 24 h (a). The cells 
were treated with 5 ng/mL transforming growth factor 1 (TGF1) for 
24 h (b). At 2 h before the addition of TGF1, the cells were treated 
with 16 M 10058-F4 (c), or with 30 M PD98059 (d). The cells were 
harvested 24 h after the TGF1 treatment and lysed. Aliquots of the 
lysates were electrophoresed on 12.5% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE). The protein bands were 
blotted to a polyvinylidene diflouride (PVDF) membrane and probed 
with antibodies against c-Myc, p15, p21, and p27. -Actin was used as 
a quantity loading control. Treatment with TGF1 without inhibitors (b) 
did not abolish c-Myc expression but decreased the level of cyclin-
dependent kinase inhibitors (CKIs) (p21, p27) compared to the control, 
while treatments with inhibitors (c, d) diminished c-Myc and upregu-
lated p21 and p27. In contrast, p15 levels were unchanged by any of 
these treatments.Available online http://arthritis-research.com/content/10/6/R140
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Figure 8
Time course study of c-Myc and phospho-extracellular signal regulated kinase (ERK)1/2 expression by western blot analysis Time course study of c-Myc and phospho-extracellular signal regulated kinase (ERK)1/2 expression by western blot analysis. Serum-
deprived nucleus pulposus cells were treated with or without 16 M 10058-F4 or 30 M PD98059 before the addition of 5 ng/mL transforming 
growth factor 1 (TGF1). The cells were harvested at the times indicated and lysed. Aliquots of the lysates were electrophoresed on 5% to 20% 
gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis SDS-PAGE). The protein bands were blotted to a polyvinylidene diflouride 
(PVDF) membrane and probed with antibodies against c-Myc, total ERK1/2 and phospho-ERK1/2. -Actin was used as a quantity loading control. 
(a) TGF1 treatment induced immediate phosphorylation of ERK1/2 with robust c-Myc expression for 2 h. The expression of c-Myc, phospho-ERK1/
2, and total ERK1/2 were detected throughout the experimental period. The right lane indicates the result of 24 h treatment with 10% FBS; c-Myc 
and phospho-ERK1/2 appear distinctly. (b) Pretreatment with ERK1/2 inhibitor 30 M PD98059 diminished the expression of c-Myc and interrupted 
the phosphorylation of ERK1/2. Note that a single isoform corresponding to phospho-ERK2 was detected at all times. (c) Pretreatment with c-Myc 
inhibitor 16 M 10058-F4 diminished c-Myc expression and limited ERK1/2 phosphorylation for a short time under TGF1 stimulation. Graphs show 
relative intensities in expression of c-Myc normalized to -actin levels and in expression of phospho-ERK1/2 normalized to total ERK1/2 levels, 
respectively.Arthritis Research & Therapy    Vol 10 No 6    Nakai et al.
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10058-F4 downregulates c-Myc expression and ERK1/2 
phosophorylation
The c-Myc inhibitor 10058-F4 we used was isolated by Yin et
al. [21] using a yeast two-hybrid system. In order to bind DNA,
c-Myc must dimerize with Max. 10058-F4 inhibits c-Myc tran-
scriptional activity by disrupting the c-Myc/Max association.
The half-life of Myc is known to be less than 30 min [51]; it has
also been reported that the instability of oncoprotein Myc is
important to avoid its accumulation in normal cells and that
Myc is destroyed by ubiquitin-mediated proteolysis [52]. In this
study, we showed almost constant levels of c-Myc mRNA
expression in nucleus pulposus cells independent of serum
concentrations (Figure 1c) and sustained c-Myc protein
expression during treatment with TGF1 (Figures 7a,b and
8a). However, inhibition of c-Myc transcriptional activity by
10058-F4 in the presence TGF1 resulted in suppression of
the mitogenic effect of TGF1 (MTT assay (Figure 3) and the
cell cycle distribution (Figures 5c, 6)). These results suggest
that c-Myc implicates in the effect of TGF1. We also
observed that 10058-F4 unexpectedly interrupted phosphor-
ylation of ERK1/2 as well as downregulating c-Myc expression
(Figure 8c). Because Myc is associated with an extraordinarily
large number of genomic sites, it can regulate complex
genomic pathways [53-55]. It was also reported that transcrip-
tional response to Myc binding differs markedly according to
context and cell type [55]. The elucidation of the role of c-Myc
in ERK1/2 phosphorylation in nucleus pulposus cells requires
further investigation.
Recent studies investigating 10058-F4 report cell cycle arrest
accompanied by suppression of c-Myc mRNA in lymphoma
[56] and the suppression of c-Myc with upregulation of levels
of p21 and p27 in myeloid leukemia [57,58]. These reports
correspond with our observations (Figure 7).
PD98059 downregulates ERK1 phosphorylation and c-
Myc expression
We show that pretreatment with PD98059 significantly
blocked the mitogenic and cell cycle promotive effects of
TGF1 (MTT assay (Figure 4) and cell cycle distribution (Fig-
ures 5d, 6)) associated with suppression of c-Myc expression
(Figure 7d). In the preliminarily experiments we also examined
a protein kinase C inhibitor peptide (19–36) obtained from
Calbiochem (Darmstadt, Germany), because inhibition of pro-
tein kinase C had been reported to cause abolition of TGF1
induced cell growth in rat articular chondrocytes [37], but it
did not exert the abolition in nucleus pulposus cells (data not
shown). By contrast, PD98059 showed a significant inhibitory
effect. PD98059 is an inhibitor for MAP kinase kinases 1 and
2 (MKK), also called MAP/ERK kinases (MEK), the upstream
activator of ERK1/2. In the time course study (Figure 8b), the
second panel shows only phospho-ERK2 protein bands with
the complete absence of phospho-ERK1 for 24 h. The inhibi-
tory effect of PD98059 on MEK2 is known to be less potent
than MEK1. The concentration of PD98059 required to give
50% inhibition (IC50) of MEK1 is 4 M and of MEK2 is 50 M
[22]. Because we used a maximum dose of 30 M of
PD98059, MEK1 was considered to be strongly inhibited.
These results suggest that phosphorylated ERK1 is necessary
to maintain c-Myc expression and promote cell cycle progres-
sion under TGF1 stimulation. Our results agree with earlier
reports showing that ERK1/2 plays a crucial mediating role in
mitogenic signaling of TGF1 in mouse BM-MSCs cultured in
chondrogenic condition [9] and in rat articular chondrocytes
[23].
Possibility of c-Myc stability supported by phospho-
ERK1/2
We showed the persistent expression of c-Myc in nucleus pul-
posus cells, which are not tumor cells or immortalized cells. As
described above, c-Myc appears to be supported by phospho-
ERK1/2. Lefevre et al. [59] showed that treatment with Raf-1
kinase inhibitor or ERK1/2 inhibitor PD98059 decreased c-
Myc production in cultured ocular choroidal melanoma which
had a high and constant level of c-Myc. Also, the contribution
of Ras/Raf/ERK prevented the rapid degradation of c-Myc by
phosphorylation of the serine 62 residue in the N-terminal of c-
Myc [24]. They also found that the suppression of glycogen
synthase kinase 3 beta (GSK-3) activity, which phosphor-
ylates threonine 58, a phosphorylation site adjacent to serine
62, enhances c-Myc stability. Although we did not analyze the
phosphorylation of c-Myc, these proposed kinetics should be
investigated to explain the enhanced stability of c-Myc in
nucleus pulposus cells.
Recent investigations have revealed that Myc stability is
required in self-renewal and maintenance of murine ES cell
pluripotency [44]. These authors evaluated Myc protein levels
in ES cells and concluded that elevated Myc activity is able to
block the differentiation of multiple cell lineages and that this
blocking of differentiation promotes self-renewal. Similarly, c-
Myc has been reported to inhibit the terminal stages of adi-
pocyte differentiation [60].
We used cells derived from rat nucleus pulposus of the
intervertebral disc to examine how they respond to TGF-1
stimulation. Cells constituting the nucleus pulposus are known
to be sparse and have a low ability for self-renewal [61].
Although efforts to regenerate disc tissue using cell therapy
have accelerated their profiling [62], the precise phenotype of
nucleus pulposus cells and their response to various cytokines
are still under investigation. In this study, we suggested a spe-
cific regulatory pathway of TGF1 in which c-Myc and phos-
pho-ERK1/2 play important roles. However, we used the third
or fourth passaged culture, which did not contain large noto-
chordal cells. Therefore, some phenotypic change (that is ded-
ifferentiation) may have been induced, as is known to occur for
articular chondrocytes. Inevitably, the correlation between dif-
ferentiation level in the cells and responsiveness to TGF1
remains to be elucidated. Moreover, in view of the therapeuticAvailable online http://arthritis-research.com/content/10/6/R140
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use of TGF1 for nucleus pulposus regeneration, the limitation
in the use of the rat model needs to be carefully considered.
This is because the presence of notochordal cells in the rat
coccygeal disc is different from the human situation, in which
notochordal cells have been known to disappear after birth.
Therefore, future studies using different animal models are
necessary to confirm whether the implication of c-Myc and
ERK1/2 can generally be attributed to nucleus pulposus cells
or it depends on the species of the donor.
Conclusion
Because our results indicate that both c-Myc and phospho-
ERK1/2 are required for proliferation and cell cycle progres-
sion, we conclude that the synergistic effect between c-Myc
and phospho-ERK1/2 plays a key role in nucleus pulposus cell
growth under TGF1 stimulation. Therefore, treatment with
TGF1 should yield different effects depending on the status
of these mediators in the target cells.
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